SECreport
Form 8-K Blueprint Medicines Corp For: Sep 30
Last blueprint medicines corp earnings: 5/9 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
| IMPACT SNAPSHOT | EVENT TIME: | BPMC | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BPMC alerts
BPMC alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corp news events
Weekly update
A roundup of the hottest topics
BPMC
NEWS
NEWS
- Blueprint Medicines Corp (NASDAQ: BPMC) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $125.00 price target on the stock.[MarketBeat]
- Blueprint Medicines Corp (NASDAQ: BPMC) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating.[MarketBeat]
- Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations[PR Newswire]
- Blueprint Medicines (BPMC) Q1 2019 Earnings Call Transcript [The Motley Fool][The Motley Fool]
- Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- More
BPMC
SEC Filings
SEC Filings
- 5/9/19 - Form 10-Q
- 5/9/19 - Form 8-K
- 4/29/19 - Form DEFA14A
- BPMC's page on the SEC website
- More